In the dynamic realm of oncology, the integration of nanotechnology into cancer vaccines is emerging as a transformative frontier. These tiny particles, measuring between 1 and 100 nanometers, are revolutionizing the wayRead More…
Influenza continues to pose a significant global threat, with seasonal outbreaks causing millions of infections, countless hospitalizations, economic disruptions, and approximately 290,000 to 650,000 annual deaths worldwide. Traditional flu vaccines, while criticalRead More…
Vaccination is undoubtedly one of the most remarkable health achievements in human history. In just over two centuries, vaccines have enabled us to achieve extraordinary goals, such as eradicating smallpox, eradicating polioRead More…
The mRNA COVID-19 vaccine has allowed us to witness the effectiveness, safety, and tremendous potential of mRNA technology. Currently, research institutions worldwide are targeting cancer as the next goal for mRNA technology.Read More…
GSK announced that its respiratory syncytial virus (RSV) vaccine Arexvy (RSVPreF3 OA/GSK3844766A) has been approved by the FDA for the prevention of lower respiratory disease (RSV-LRTD) caused by RSV infection in theRead More…
Traditional vaccines are committed to the prevention of a variety of infectious diseases, while cancer vaccines, which have attracted much attention in recent years, aim to focus the strength of the humanRead More…